Clinical Trial · NCT07505069

Exploring the Clinical Value of RT01-89Zr PET Imaging in Solid Tumors

Overview

RT01-89Zr is a TF-targeting radiopharmaceutical diagnostic agent. This trial aims to evaluate the safety, biodistribution, dosimetry, and imaging characteristics of RT01-89Zr as a PET/CT tracer in patients with malignant solid tumors that highly express the TF target.

Sponsor

Primo Biotechnology Co., Ltd

Phase

Early Phase 1

Contacts

Jingchun Yu (CONTACT)

ycjwxd1978@jiangnan.edu.cn

0510-68089404

ClinicalTrials.gov

NCT07505069

Drug / Compound

RT01

Isotope(s):

Target(s):

Tissue Factor

Ligand Class: Antibodies

Eligibility

Inclusion

During the screening period, tumor tissue samples (either archived previously or freshly biopsied) can be provided, with positive target expression of more than 1%;
Confirmed as a solid tumor by histopathology or cytology;
ECOG Performance Status: 0 or 1;
At least one primary or metastatic lesion confirmed by conventional imaging；

Exclusion

Those who have received radiopharmaceuticals before administration and whose discontinuation duration does not exceed 5 half-lives;